Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod

BACKGROUND: Fingolimod is a once-daily oral treatment for relapsing multiple sclerosis, the proprietary production processes of which are tightly controlled, owing to its susceptibility to contamination by impurities, including genotoxic impurities. Many markets produce nonproprietary medicines; ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Correale, Jorge, Chiquete, Erwin, Milojevic, Snezana, Frider, Nadina, Bajusz, Imre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077387/
https://www.ncbi.nlm.nih.gov/pubmed/25028537
http://dx.doi.org/10.2147/DDDT.S66398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077387/
https://www.ncbi.nlm.nih.gov/pubmed/25028537
http://dx.doi.org/10.2147/DDDT.S66398

Ejemplares similares